Выбор оптимальной комбинации нейрогуморальных модуляторов при хронической сердечной недостаточности: уроки исследования CHARM-Added
Аннотация
Статья посвящена выбору оптимальных доз и комбинаций нейрогуморальных модуляторов при систолической дисфункции левого желудочка и сердечной недостаточности. Проанализированы результаты исследований CHARM-Added, Val-HeFT, RALES, EPHESUS и их влияние на современные рекомендации по диагностике и лечению хронической сердечной недостаточности.
Об авторе
Ю. М. Лопатин
Волгоградский государственный медицинский университет, Волгоградский областной кардиологический центр, Волгоград
Россия
Россия
Список литературы
1. Guidelines for the diagnosis and treatment of Chronic Heart Failure: full text (update 2005). The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology. Eur Heart J doi: 10.1093/eurheartj/ehi205.
2. ACC/AHA 2005 Guideline Update for the Diagnosis and management of Chronic Heart failure in the Adult Report of the American College of Cardiology. American Heart Association Task Force on practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and management of Heart Failure. http: www.acc.org/qualityandscience/ clinical/guidelines/failure/update/index.pdf.
3. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). Ж серд недост 2007; 8 (2): 35 с.
4. Gheorghiade M, Ferguson D. Digoxin: a neurohormonal modulator in heart failure? Circulation 1991; 84: 2181-6.
5. The NETWORK investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: A dose comparison. Eur Heart J 1998; 19: 481-9.
6. ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting-enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-8.
7. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, et al. for the High Enalapril Dose Study Group. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study JACC 2000; 36: 2090-5.
8. Wikstrand J, Hjalmarson A, Waagstein F, et al. For the MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). JACC 2002; 40: 491-8.
9. Simon T, Mary-Krause M, Funck-Bretano C, et al. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J 2003; 24: 552-9.
10. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. – М осква «ГЕОТАР-Медиа» 2006; – 432 с.
11. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotension-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6.
12. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-81.
13. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotension-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
14. Pitt B, Zannad F, Remme WJ, et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEngl J Med 1999; 341: 709-17.
15. Pitt B, Remme W, Zanad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
16. Cohn JN, Tognoni G, Valsatan Heart failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. NEnglJ Med 2001; 345: 1667-75.
17. McMurray JJV, Pfeffer MA, Swedberg K, et al. Which Inhibitor of the Renin-Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? Circulation 2004; 110: 3281-8.
18. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. EurHeart J 2001; 22: 1527-60.
19. McMurray JJV, Young JB, Dunlap ME, et al. Relationship of dose background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-Added trial. Am Heart J 2006; 151: 992-8.
Для цитирования:
Лопатин Ю.М. Выбор оптимальной комбинации нейрогуморальных модуляторов при хронической сердечной недостаточности: уроки исследования CHARM-Added. Кардиоваскулярная терапия и профилактика. 2007;6(3):76-81.
For citation:
Lopatin Y.M. Choosing optimal combination of neuro-humoral modulators in chronic heart failure: CHARM-Added study lessons. Cardiovascular Therapy and Prevention. 2007;6(3):76-81. (In Russ.)
Просмотров: 11
Послать статью по эл. почте 
